Rani Therapeutics Holdings, Inc.

RANI Nasdaq SEC CIK 1856725
Follow Rani Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $1.7M
Net income −$7.7M −42.8% vs same quarter last year
EPS, diluted −$0.04 +66.7% vs same quarter last year
Operating cash flow −$7.8M −53.3% vs same quarter last year
Revenue by quarter
$1M
$172K
$0
$0
$1.5M
$1.7M
$1.7M
$1.7M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
  • Revenue
  • Net income
−$40M−$30M−$20M−$10M$0$10MFY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$1.6M−$29.7M
FY24$1M−$30M
FY23$0−$34M
FY22$0−$30.6M
FY21$2.7M−$8.3M
FY20$462K−$16.7M
MarginsShare of revenue
  • Operating margin
  • Net margin
−6000%−4000%−2000%0%FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−2346%−1817.1%
FY24−5186.2%−2920%
FY23--
FY22--
FY21−1899.1%−306.6%
FY20−3581%−3615.4%
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$18.8M
FY24−$35.8M
FY23−$52.5M
FY22−$48.1M
FY21−$32.8M
FY20−$16.2M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Rani Therapeutics
  • Healthcare median
−4000%−3000%−2000%−1000%0%FY20FY21FY22FY23FY24FY25
Show the numbers
YearRani TherapeuticsHealthcare median
FY25−1817.1%−30.6%
FY24−2920%−47%
FY23-−58%
FY22-−80.4%
FY21−306.6%−71.9%
FY20−3615.4%−62.2%